CSPC Shengxue Glucose Co.,Ltd. announced that it expects to receive CNY 260 million in funding from CSPC Innovation Pharmaceutical Co., Ltd.
March 14, 2023
Share
CSPC Shengxue Glucose Co.,Ltd. announced that it will raise CNY 260,000,000 in an equity round of funding on March 15, 2023. The transaction will include participation from returning investor, CSPC Innovation Pharmaceutical Co., Ltd. The company's registered capital will increase from CNY 434,910,000 to CNY 500,000,000. The transaction has been approved by the 28th meeting of the fifth board of directors and the 26th meeting of the fifth board of supervisors.
On June 14, 2023, the company announced that has completed the industrial and commercial registration procedures required for the capital increase and obtained a new business license issued by the Administrative Approval Bureau of Luancheng District, Shijiazhuang City.
CSPC Innovation Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of functional ingredients. The Company operates two segments. Functional Ingredients segment mainly provides caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, theophylline, theobromine, pentoxifylline, doxofylline, and biological enzymes. Health Food Products segment mainly provides Guoweikang Vitamin C tablets, Guoweikang B vitamin lozenges, and others. The Company mainly conducts businesses within the domestic market.